| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
RNS/INCREDIBLE NEWS.FUNDING+8M CONTACT (XCT)
caz80 - 14 Dec 2009 15:42
E*TRADE View E*TRADE Products & Accounts Help
*
Accounts
*
Investing
*
Tools &
Research
Quote:
Logoff
*
Markets
* |
*
News
*
Company Profile
*
Charts
* |
*
Stock Screener
* |
*
Heat Maps
* |
*
Performance Tables
* |
*
Technical Analysis
14 Dec, 2009 15:41 UK
Symbol Lookup
FTSE 1005,309.2847.71
Close
* Snapshot
* Charts
* Prices
* Trades
* News
* Broker Views
* Director Dealings
* Star Ratings
* Fundamentals
* Profile
XCounter AB (XCT) Buy Now Sell Now
Annual Report
Sector:
Health Care Equipment & Services
Share Price
5.50p
Change Today
0.000p
Market Cap
2.40m
* Overview
* Regulatory News
* ShareCast
Subsidiary signs major development agreement
RNS Number : 0851E
XCounter AB
14 December 2009
PRESS RELEASE
XCounter's subsidiary signs major development agreement to supply innovative monitoring detectors to the energy industry
Stockholm, 14 December 2009: XCounter AB (AIM: XCT) ('XCounter' or 'the Company'), a leader in the development of photon counting detector and tomosynthesis-based 3D imaging technology, today announces that its subsidiary, Oy AJAT Ltd ("AJAT"), has signed a seven year exclusive agreement to supply its X-ray detector technology to a Norwegian company specializing in industrial technology development within the energy industry (the "Commercial Partner").
Pursuant to the agreement, AJAT will receive orders with minimum purchase values increasing each year up to and including 2015 and worth in aggregate 8.2m. The Commercial Partner has the option to extend the contract by two years on three occasions up to a total of six years.
AJAT and the Commercial Partner will work together on the development of these new detector products and other related technologies with broader applications to the energy industry.
AJAT and the Commercial Partner have been working together and have already completed the first stage of the customized technology for detection devices.
This agreement is a major step in XCounter's strategy to focus on specialty digital detector technologies for medical, dental and industrial applications.
XCounter owns 49.8% of AJAT and has a call option for the remaining 50.2%.
Mikael Strindlund, CEO of XCounter commented:
"Today's announcement is a further validation of our focus on developing and marketing specialty X-ray detector technologies for different application fields. We are delighted to have entered into this long term agreement and are looking forward to further developing our relationship with this key customer.
caz80 - 16 Dec 2009 08:23 - 21 of 23
1st detector orderedXCounter AB
XCounter AB and Artemis Imaging GmbH to develop breast CT scanner
2 July 2009: XCounter AB (publ) (AIM: XCT), a technology leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging, today announced it is working with Artemis Imaging GmbH, a spinoff of the University of Erlangen's Institute of Medical Physics, on the development of an innovative 3D Breast CT system. The new device may have the potential to offer more comprehensive and higher quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found in women.
Artemis Imaging GmbH, under the leadership of Prof. Willi Kalender, has substantial expertise and a proven track record in CT physics, system and applications development. It intends to develop, validate, clinically test and commercialize a low-dose, high-resolution breast CT scanner using the XCounter digital direct conversion solid state detector technology.
The new device will offer multiple views of the breast, while XCounter's photon counting technology will increase the overall quality of imaging.
Prof. Willi Kalender, CEO of Artemis Imaging GmbH stated:
"We selected the XCounter photon counting technology because we believe it meets the requirements for a revolutionary new dedicated breast CT system which combines the highest image quality with the lowest radiation dose to the patient."
Mikael Strindlund, CEO of XCounter commented:
"Today's announcement is further validation, by world-renown experts, of our leading photon counting solid state detectors and its potential to assist in the earlier identification of one of the most common forms of cancer."
XCounter's technology includes recently acquired AJAT technologies and XCounter's photon counting technology. Artemis Imaging GmbH aims to qualify the technology as soon as it becomes available; a first detector has already been ordered for evaluation.
XCounter AB and Artemis Imaging GmbH to develop breast CT scanner
2 July 2009: XCounter AB (publ) (AIM: XCT), a technology leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging, today announced it is working with Artemis Imaging GmbH, a spinoff of the University of Erlangen's Institute of Medical Physics, on the development of an innovative 3D Breast CT system. The new device may have the potential to offer more comprehensive and higher quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found in women.
Artemis Imaging GmbH, under the leadership of Prof. Willi Kalender, has substantial expertise and a proven track record in CT physics, system and applications development. It intends to develop, validate, clinically test and commercialize a low-dose, high-resolution breast CT scanner using the XCounter digital direct conversion solid state detector technology.
The new device will offer multiple views of the breast, while XCounter's photon counting technology will increase the overall quality of imaging.
Prof. Willi Kalender, CEO of Artemis Imaging GmbH stated:
"We selected the XCounter photon counting technology because we believe it meets the requirements for a revolutionary new dedicated breast CT system which combines the highest image quality with the lowest radiation dose to the patient."
Mikael Strindlund, CEO of XCounter commented:
"Today's announcement is further validation, by world-renown experts, of our leading photon counting solid state detectors and its potential to assist in the earlier identification of one of the most common forms of cancer."
XCounter's technology includes recently acquired AJAT technologies and XCounter's photon counting technology. Artemis Imaging GmbH aims to qualify the technology as soon as it becomes available; a first detector has already been ordered for evaluation.
caz80 - 16 Dec 2009 12:04 - 22 of 23
dtechinsight.com/ReportA409.html. It is a snapshot of the page as it appeared on 5 Dec 2009 22:09:03 GMT. The current page could have changed in the meantime. Learn more
Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer
Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009
Online Report Subscribers, Click Here
Pricing and Ordering Information
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles
According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.
The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.
As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.
This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.
Ordering Information
Title
Report# Publication
Date List Price
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
A409
October 2009
$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only
Print versions of Reports are available upon request for an additional fee.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
i. Common Types of Breast Cancer
ii. Symptoms
iii. Risk Factors
iv. Early Detection
v. Treatment
vi. Risk Reduction
vii. Future Directions in Breast Cancer Detection
viii. Breast Cancer Detection and Diagnostic Technologies Market
Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit ES-6: Selected Limitations of Mammography
Exhibit ES-7: Selected Breast Cancer Imaging Technologies
Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013
Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier
1. CLINICAL overview
1.1 Common Types of Breast Cancer
1.2 Symptoms
1.3 Risk Factors
1.3.1 Benign Breast Conditions
1.3.2 Family/Personal History
1.3.3 Genetic Risks
1.4 Early Detection
1.5 Treatment
1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy
1.6 Risk Reduction
1.7 Future Trends in Breast Cancer Detection
Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit 1-6: Benign Breast Disease, by Category
Exhibit 1-7: Selected Benign Breast Diseases
Exhibit 1-8: Selected Limitations of Mammography
Exhibit 1-9: Selected Breast Cancer Imaging Technologies
2. MAMMOGRAPHY
2.1 Analog Mammography Systems
2.1.1 GE Healthcare/General Electric
2.1.2 Hologic
2.1.3 Planmed/Planmeca Group
2.1.4 Siemens Healthcare/Siemens
2.1.5 Others
2.2 Digital Mammography Systems
2.2.1 GE Healthcare/General Electric
2.2.2 Hologic
2.2.3 Siemens Healthcare/Siemens
2.2.4 Others
2.3 Computer-Aided Detection
2.3.1 Carestream Health/Onex
2.3.2 Hologic
2.3.3 iCAD
2.3.4 Scanis
2.4 Emerging Mammography Technology
2.4.1 BBN Technologies
2.4.2 Dexela
2.4.3 GE Healthcare/General Electric
2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings
2.4.5 Hologic
2.4.6 Imaging Diagnostic Systems
2.4.7 Philips Healthcare/Royal Philips Electronics
2.4.8 Sectra
2.4.9 Siemens Healthcare/Siemens
2.4.10 XCounter
2.4.11 Others
Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer
Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009
Online Report Subscribers, Click Here
Pricing and Ordering Information
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles
According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.
The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.
As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.
This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.
Ordering Information
Title
Report# Publication
Date List Price
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
A409
October 2009
$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only
Print versions of Reports are available upon request for an additional fee.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
i. Common Types of Breast Cancer
ii. Symptoms
iii. Risk Factors
iv. Early Detection
v. Treatment
vi. Risk Reduction
vii. Future Directions in Breast Cancer Detection
viii. Breast Cancer Detection and Diagnostic Technologies Market
Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit ES-6: Selected Limitations of Mammography
Exhibit ES-7: Selected Breast Cancer Imaging Technologies
Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013
Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier
1. CLINICAL overview
1.1 Common Types of Breast Cancer
1.2 Symptoms
1.3 Risk Factors
1.3.1 Benign Breast Conditions
1.3.2 Family/Personal History
1.3.3 Genetic Risks
1.4 Early Detection
1.5 Treatment
1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy
1.6 Risk Reduction
1.7 Future Trends in Breast Cancer Detection
Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit 1-6: Benign Breast Disease, by Category
Exhibit 1-7: Selected Benign Breast Diseases
Exhibit 1-8: Selected Limitations of Mammography
Exhibit 1-9: Selected Breast Cancer Imaging Technologies
2. MAMMOGRAPHY
2.1 Analog Mammography Systems
2.1.1 GE Healthcare/General Electric
2.1.2 Hologic
2.1.3 Planmed/Planmeca Group
2.1.4 Siemens Healthcare/Siemens
2.1.5 Others
2.2 Digital Mammography Systems
2.2.1 GE Healthcare/General Electric
2.2.2 Hologic
2.2.3 Siemens Healthcare/Siemens
2.2.4 Others
2.3 Computer-Aided Detection
2.3.1 Carestream Health/Onex
2.3.2 Hologic
2.3.3 iCAD
2.3.4 Scanis
2.4 Emerging Mammography Technology
2.4.1 BBN Technologies
2.4.2 Dexela
2.4.3 GE Healthcare/General Electric
2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings
2.4.5 Hologic
2.4.6 Imaging Diagnostic Systems
2.4.7 Philips Healthcare/Royal Philips Electronics
2.4.8 Sectra
2.4.9 Siemens Healthcare/Siemens
2.4.10 XCounter
2.4.11 Others
caz80 - 16 Dec 2009 12:04 - 23 of 23
dtechinsight.com/ReportA409.html. It is a snapshot of the page as it appeared on 5 Dec 2009 22:09:03 GMT. The current page could have changed in the meantime. Learn more
Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer
Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009
Online Report Subscribers, Click Here
Pricing and Ordering Information
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles
According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.
The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.
As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.
This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.
Ordering Information
Title
Report# Publication
Date List Price
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
A409
October 2009
$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only
Print versions of Reports are available upon request for an additional fee.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
i. Common Types of Breast Cancer
ii. Symptoms
iii. Risk Factors
iv. Early Detection
v. Treatment
vi. Risk Reduction
vii. Future Directions in Breast Cancer Detection
viii. Breast Cancer Detection and Diagnostic Technologies Market
Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit ES-6: Selected Limitations of Mammography
Exhibit ES-7: Selected Breast Cancer Imaging Technologies
Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013
Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier
1. CLINICAL overview
1.1 Common Types of Breast Cancer
1.2 Symptoms
1.3 Risk Factors
1.3.1 Benign Breast Conditions
1.3.2 Family/Personal History
1.3.3 Genetic Risks
1.4 Early Detection
1.5 Treatment
1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy
1.6 Risk Reduction
1.7 Future Trends in Breast Cancer Detection
Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit 1-6: Benign Breast Disease, by Category
Exhibit 1-7: Selected Benign Breast Diseases
Exhibit 1-8: Selected Limitations of Mammography
Exhibit 1-9: Selected Breast Cancer Imaging Technologies
2. MAMMOGRAPHY
2.1 Analog Mammography Systems
2.1.1 GE Healthcare/General Electric
2.1.2 Hologic
2.1.3 Planmed/Planmeca Group
2.1.4 Siemens Healthcare/Siemens
2.1.5 Others
2.2 Digital Mammography Systems
2.2.1 GE Healthcare/General Electric
2.2.2 Hologic
2.2.3 Siemens Healthcare/Siemens
2.2.4 Others
2.3 Computer-Aided Detection
2.3.1 Carestream Health/Onex
2.3.2 Hologic
2.3.3 iCAD
2.3.4 Scanis
2.4 Emerging Mammography Technology
2.4.1 BBN Technologies
2.4.2 Dexela
2.4.3 GE Healthcare/General Electric
2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings
2.4.5 Hologic
2.4.6 Imaging Diagnostic Systems
2.4.7 Philips Healthcare/Royal Philips Electronics
2.4.8 Sectra
2.4.9 Siemens Healthcare/Siemens
2.4.10 XCounter
2.4.11 Others
Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer
Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009
Online Report Subscribers, Click Here
Pricing and Ordering Information
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles
According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.
The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.
As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.
This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.
Ordering Information
Title
Report# Publication
Date List Price
U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
A409
October 2009
$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only
Print versions of Reports are available upon request for an additional fee.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
i. Common Types of Breast Cancer
ii. Symptoms
iii. Risk Factors
iv. Early Detection
v. Treatment
vi. Risk Reduction
vii. Future Directions in Breast Cancer Detection
viii. Breast Cancer Detection and Diagnostic Technologies Market
Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit ES-6: Selected Limitations of Mammography
Exhibit ES-7: Selected Breast Cancer Imaging Technologies
Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013
Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment
Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier
1. CLINICAL overview
1.1 Common Types of Breast Cancer
1.2 Symptoms
1.3 Risk Factors
1.3.1 Benign Breast Conditions
1.3.2 Family/Personal History
1.3.3 Genetic Risks
1.4 Early Detection
1.5 Treatment
1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy
1.6 Risk Reduction
1.7 Future Trends in Breast Cancer Detection
Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009
Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage
Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis
Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer
Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age
Exhibit 1-6: Benign Breast Disease, by Category
Exhibit 1-7: Selected Benign Breast Diseases
Exhibit 1-8: Selected Limitations of Mammography
Exhibit 1-9: Selected Breast Cancer Imaging Technologies
2. MAMMOGRAPHY
2.1 Analog Mammography Systems
2.1.1 GE Healthcare/General Electric
2.1.2 Hologic
2.1.3 Planmed/Planmeca Group
2.1.4 Siemens Healthcare/Siemens
2.1.5 Others
2.2 Digital Mammography Systems
2.2.1 GE Healthcare/General Electric
2.2.2 Hologic
2.2.3 Siemens Healthcare/Siemens
2.2.4 Others
2.3 Computer-Aided Detection
2.3.1 Carestream Health/Onex
2.3.2 Hologic
2.3.3 iCAD
2.3.4 Scanis
2.4 Emerging Mammography Technology
2.4.1 BBN Technologies
2.4.2 Dexela
2.4.3 GE Healthcare/General Electric
2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings
2.4.5 Hologic
2.4.6 Imaging Diagnostic Systems
2.4.7 Philips Healthcare/Royal Philips Electronics
2.4.8 Sectra
2.4.9 Siemens Healthcare/Siemens
2.4.10 XCounter
2.4.11 Others
- Page:
- 1
- 2
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter